SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009
Go back to SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009| RiverSource LaSalle Internatio (NASDAQ: SLS) | Delayed: 14.98 +1.71 (12.89%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.27 | 52 Week High | $10.16 | |||
| Open | $13.20 | 52 Week Low | $6.52 | |||
| Day High | $15.05 | P/E | N/A | |||
| Day Low | $12.95 | EPS | $0.00 | |||
| Volume | 17,275,570 | |||||
